| 1 |
Song W, Ding N, Zhang X, Liu J, Wang Y, Yan J, Liu S. Mean Platelet Volume Enhances the Diagnostic Specificity of PSA for Prostate Cancer. Front Surg 2022;9:845288. [DOI: 10.3389/fsurg.2022.845288] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 2 |
Jazireian P, Sasani ST, Assarzadegan F, Azimian M. TRAILR1 (rs20576) and GRIA3 (rs12557782) are not associated with interferon-β response in multiple sclerosis patients. Mol Biol Rep 2020;47:9659-65. [PMID: 33269432 DOI: 10.1007/s11033-020-06026-w] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 3 |
Kim J, Chung JY, Hwang JR, Lee YY, Kim TJ, Lee JW, Kim BG, Bae DS, Choi CH, Hewitt SM. Identification of Candidate Genes Associated with Susceptibility to Ovarian Clear Cell Adenocarcinoma Using cis-eQTL Analysis. J Clin Med 2020;9:E1137. [PMID: 32316112 DOI: 10.3390/jcm9041137] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 4 |
Han KWW, Po WW, Sohn UD, Kim HJ. Benzyl Isothiocyanate Induces Apoptosis via Reactive Oxygen Species-Initiated Mitochondrial Dysfunction and DR4 and DR5 Death Receptor Activation in Gastric Adenocarcinoma Cells. Biomolecules 2019;9:E839. [PMID: 31817791 DOI: 10.3390/biom9120839] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 5 |
Renner W, Krenn-Pilko S, Gruber HJ, Herrmann M, Langsenlehner T. Relative telomere length and prostate cancer mortality. Prostate Cancer Prostatic Dis 2018;21:579-83. [PMID: 30082901 DOI: 10.1038/s41391-018-0068-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.6] [Reference Citation Analysis]
|
| 6 |
Renner W, Langsenlehner U, Krenn-Pilko S, Eder P, Langsenlehner T. BCL2 genotypes and prostate cancer survival. Strahlenther Onkol 2017;193:466-71. [PMID: 28396899 DOI: 10.1007/s00066-017-1126-9] [Cited by in Crossref: 15] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 7 |
Trummer O, Langsenlehner U, Krenn-Pilko S, Pieber TR, Obermayer-Pietsch B, Gerger A, Renner W, Langsenlehner T. Vitamin D and prostate cancer prognosis: a Mendelian randomization study. World J Urol 2016;34:607-11. [PMID: 26209090 DOI: 10.1007/s00345-015-1646-9] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 8 |
Langsenlehner T, Pichler M, Thurner EM, Krenn-Pilko S, Stojakovic T, Gerger A, Langsenlehner U. Evaluation of the platelet-to-lymphocyte ratio as a prognostic indicator in a European cohort of patients with prostate cancer treated with radiotherapy. Urol Oncol 2015;33:201.e9-16. [PMID: 25769845 DOI: 10.1016/j.urolonc.2015.02.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
|
| 9 |
Mittal RD, Mandal RK, Singh A, Srivastava P. Death receptor 4 variants enhanced prostate cancer risk in North Indian population. Tumor Biol 2015;36:5655-61. [DOI: 10.1007/s13277-015-3239-z] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
|
| 10 |
Chen Y, Yuan K, Mcdonald J. Pancreatic Cancer Resistance to TRAIL Therapy: Regulators of the Death Inducing Signaling Complex. Resistance to Targeted Anti-Cancer Therapeutics 2015. [DOI: 10.1007/978-3-319-17807-3_11] [Reference Citation Analysis]
|
| 11 |
Heredia-galvez B, Ruiz-cosano J, Torres-moreno D, Español I, Morales-lara MJ, Pérez-ceballos E, González-conejero R, Gutiérrez-cívicos R, Vicente V, Pérez-guillermo M, Conesa-zamora P. Association of polymorphisms in TRAIL1 and TRAILR1 genes with susceptibility to lymphomas. Ann Hematol 2014;93:243-7. [DOI: 10.1007/s00277-013-1864-4] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 12 |
López-Gómez C, Pino-Ángeles A, Órpez-Zafra T, Pinto-Medel MJ, Oliver-Martos B, Ortega-Pinazo J, Arnáiz C, Guijarro-Castro C, Varadé J, Álvarez-Lafuente R, Urcelay E, Sánchez-Jiménez F, Fernández Ó, Leyva L. Candidate gene study of TRAIL and TRAIL receptors: association with response to interferon beta therapy in multiple sclerosis patients. PLoS One 2013;8:e62540. [PMID: 23658636 DOI: 10.1371/journal.pone.0062540] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 13 |
Langsenlehner T, Renner W, Gerger A, Hofmann G, Thurner E, Kapp KS, Langsenlehner U. Impact of VEGF gene polymorphisms and haplotypes on radiation-induced late toxicity in prostate cancer patients. Strahlenther Onkol 2011;187:784-91. [DOI: 10.1007/s00066-011-1106-4] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 14 |
Voelkel-Johnson C. TRAIL-mediated signaling in prostate, bladder and renal cancer. Nat Rev Urol 2011;8:417-27. [PMID: 21670755 DOI: 10.1038/nrurol.2011.81] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 2.9] [Reference Citation Analysis]
|
| 15 |
Langsenlehner T, Renner W, Gerger A, Hofmann G, Thurner EM, Kapp KS, Langsenlehner U. Association between single nucleotide polymorphisms in the gene for XRCC1 and radiation-induced late toxicity in prostate cancer patients. Radiother Oncol 2011;98:387-93. [PMID: 21345510 DOI: 10.1016/j.radonc.2011.01.021] [Cited by in Crossref: 38] [Cited by in F6Publishing: 39] [Article Influence: 3.2] [Reference Citation Analysis]
|
| 16 |
Jung JH, Chae YS, Moon JH, Kang BW, Kim JG, Sohn SK, Park JY, Lee MH, Park HY. TNF superfamily gene polymorphism as prognostic factor in early breast cancer. J Cancer Res Clin Oncol 2010;136:685-94. [PMID: 19890662 DOI: 10.1007/s00432-009-0707-0] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 17 |
Wang M, Wang M, Cheng G, Zhang Z, Fu G, Zhang Z. Genetic variants in the death receptor 4 gene contribute to susceptibility to bladder cancer. Mutat Res 2009;661:85-92. [PMID: 19070628 DOI: 10.1016/j.mrfmmm.2008.11.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
|
| 18 |
Langsenlehner T, Kapp KS, Langsenlehner U. TGFB1 single-nucleotide polymorphisms are associated with adverse quality of life in prostate cancer patients treated with radiotherapy. In regard to Peters et al. (Int J Radiat Oncol Biol Phys 2008;70:752-759). Int J Radiat Oncol Biol Phys 2008;71:960; author reply 960-1. [PMID: 18514790 DOI: 10.1016/j.ijrobp.2008.02.029] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 19 |
Langsenlehner T, Langsenlehner U, Renner W, Krippl P, Mayer R, Wascher TC, Kapp KS. Single nucleotide polymorphisms and haplotypes in the gene for vascular endothelial growth factor and risk of prostate cancer. Eur J Cancer 2008;44:1572-6. [PMID: 18514506 DOI: 10.1016/j.ejca.2008.04.021] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
|
